Kemprud E.P.,Amador Valley Medical Center |
Montano S.A.,ImmunoScience Inc |
Kalbag G.S.,Amador Valley Medical Center |
Tam A.S.O.,Amador Valley Medical Center |
And 2 more authors.
European Infectious Disease | Year: 2011
The current methods of detecting exposure to HIV types 1 and 2 involve a serum enzyme-linked immunosorbent assay (ELISA), Western immunoblotting and polymerase chain reaction (PCR). All of these techniques require collection of blood, trained personnel and sophisticated lab facilities. There is also an inherent danger in collection of blood samples, especially in environments where disposable needles are not commonly used. As a result, the prevalent methods are impractical for use in the field and for mass screening, particularly in the developing world and in epidemic situations. This study compared a saliva-based rapid immunoassay with conventional ELISA. A total of 1,192 paired samples of saliva and blood from six Northern California locations were obtained. The saliva samples were subjected to the Salivax™ HIV immunoassay and the blood/serum samples were tested with US Food and Drug Administration (FDA)-approved BioRad® enzyme immunoassay (EIA) in a College of American Pathologists (CAP)-certified laboratory. The comparison of results showed Salivax HIV to have a sensitivity of 99.53 % and a specificity of 99.74 %. This study confirms several prior studies that indicated that saliva is an extremely useful biological fluid for antibody screening and further indicates that Salivax HIV has the necessary sensitivity and specificity to act as a screening test, particularly in the highly populated, developing and rural world and as a point-of-care test. © Touch Briefings 2011. Source